Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/28867
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ojaimi S. | en |
dc.contributor.author | Purcell R. | en |
dc.contributor.author | Doherty R. | en |
dc.date.accessioned | 2021-05-14T09:43:38Z | en |
dc.date.available | 2021-05-14T09:43:38Z | en |
dc.date.copyright | 2020 | en |
dc.date.created | 20200504 | en |
dc.date.issued | 2020-05-04 | en |
dc.identifier.citation | Journal of Paediatrics and Child Health. 56 (4) (pp 658-659), 2020. Date of Publication: 01 Apr 2020. | en |
dc.identifier.issn | 1034-4810 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/28867 | en |
dc.language | en | en |
dc.publisher | Blackwell Publishing (E-mail: info@asia.blackwellpublishing.com) | en |
dc.relation.ispartof | Journal of Paediatrics and Child Health | en |
dc.subject.mesh | highly active antiretroviral therapy | - |
dc.subject.mesh | immunodeficiency virus infection | - |
dc.subject.mesh | hypoxic ischemic encephalopathy/co | - |
dc.subject.mesh | infection | - |
dc.subject.mesh | infection risk | - |
dc.subject.mesh | liver toxicity | - |
dc.subject.mesh | mixed infection | - |
dc.subject.mesh | monotherapy | - |
dc.subject.mesh | newborn | - |
dc.subject.mesh | opportunistic infection/co | - |
dc.subject.mesh | patient attitude | - |
dc.subject.mesh | perinatal infection/co | - |
dc.subject.mesh | prematurity/co | - |
dc.subject.mesh | protein function | - |
dc.subject.mesh | syphilis | - |
dc.subject.mesh | tuberculosis | - |
dc.subject.mesh | virus load | - |
dc.subject.mesh | antiretrovirus agent/it [Drug Interaction] | - |
dc.subject.mesh | antiretrovirus agent | - |
dc.subject.mesh | cytochrome P450 | - |
dc.subject.mesh | isoniazid | - |
dc.subject.mesh | isoniazid/it [Drug Interaction] | - |
dc.subject.mesh | lamivudine | - |
dc.subject.mesh | nevirapine | - |
dc.subject.mesh | nevirapine/it [Drug Interaction] | - |
dc.subject.mesh | nevirapine/ig [Intragastric Drug Administration] | - |
dc.subject.mesh | rifampicin | - |
dc.subject.mesh | rifampicin/it [Drug Interaction] | - |
dc.subject.mesh | virus DNA | - |
dc.subject.mesh | virus RNA | - |
dc.subject.mesh | zidovudine/it [Drug Interaction] | - |
dc.subject.mesh | zidovudine | - |
dc.subject.mesh | AIDS patient | - |
dc.subject.mesh | cytomegalovirus infection | - |
dc.subject.mesh | disease transmission | - |
dc.subject.mesh | drug absorption | - |
dc.subject.mesh | drug clearance | - |
dc.subject.mesh | drug dose titration | - |
dc.subject.mesh | drug metabolism | - |
dc.subject.mesh | gastrointestinal absorption | - |
dc.subject.mesh | genotype | - |
dc.subject.mesh | gestational age | - |
dc.subject.mesh | high risk patient | - |
dc.title | Letter to the Editor. | en |
dc.type | Letter | en |
dc.identifier.affiliation | Paediatric - Infection and Immunity | - |
dc.type.studyortrial | Opinion, perspective or news | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/jpc.14851 | - |
dc.publisher.place | Australia | en |
dc.identifier.pubmedid | 32307776 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32307776] | en |
dc.identifier.source | 2004713066 | en |
dc.identifier.institution | (Purcell, Doherty, Ojaimi) Department of Paediatric Infection and Immunity, Monash Children's Hospital, Melbourne, VIC, Australia (Doherty) Department of Paediatrics, Monash University, Melbourne, VIC, Australia | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2020 Elsevier B.V., All rights reserved. | en |
item.fulltext | No Fulltext | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Letter | - |
crisitem.author.dept | Infectious Diseases and Clinical Microbiology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.